HUP0200152A2 - Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites - Google Patents

Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites

Info

Publication number
HUP0200152A2
HUP0200152A2 HU0200152A HUP0200152A HUP0200152A2 HU P0200152 A2 HUP0200152 A2 HU P0200152A2 HU 0200152 A HU0200152 A HU 0200152A HU P0200152 A HUP0200152 A HU P0200152A HU P0200152 A2 HUP0200152 A2 HU P0200152A2
Authority
HU
Hungary
Prior art keywords
ectoparasites
inhibitors
kqt1
medicament
utilization
Prior art date
Application number
HU0200152A
Other languages
Hungarian (hu)
Inventor
Uwe Gerlach
Joachim Hofmann
Hans Jochen Lang
Aguan Wei
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Publication of HUP0200152A2 publication Critical patent/HUP0200152A2/en
Publication of HUP0200152A3 publication Critical patent/HUP0200152A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

A KQT1 csatorna inhibitorok alkalmazása a parazita férgek ésektoparaziták irtásának új elvét jelenti. Ezért a parazita férgekbenés ektoparazitákban előforduló celluláris KQT1 csatornák gátlóialkalmasak olyan gyógyszerkészítmények előállítására, amelyek parazitaférgek és ektoparaziták által fertőzött emberek és gerinces állatokkezelésére alkalmasak. A KQT1 inhibitorok gyógyszerként alkalmazhatókönmagukban vagy más gyógyszer-hatóanyagokkal kombinálva. A KQT1csatorna inhibitorok ezenkívül új hatásmechanizmust mutatnaknövénykárosító rovarok, pókok, puhatestűek és fonalférgek ellen, ezértnövényvédő szerek előállítására alkalmasak. ÓThe use of KQT1 channel inhibitors represents a new principle in the eradication of parasitic worms and ectoparasites. Therefore, inhibitors of the cellular KQT1 channels found in parasitic worms and ectoparasites are suitable for the production of pharmaceutical preparations suitable for the treatment of humans and vertebrates infected by parasitic worms and ectoparasites. KQT1 inhibitors can be used as drugs alone or in combination with other drugs. In addition, KQT1 channel inhibitors show a new mechanism of action against plant-damaging insects, spiders, molluscs and nematodes, and are therefore suitable for the production of plant protection agents. HE

HU0200152A 1998-12-17 1999-12-07 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites HUP0200152A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19858253A DE19858253A1 (en) 1998-12-17 1998-12-17 Use of KQt1 channel inhibitors for the manufacture of a medicament for the treatment of diseases caused by helminths and ectoparasites

Publications (2)

Publication Number Publication Date
HUP0200152A2 true HUP0200152A2 (en) 2002-05-29
HUP0200152A3 HUP0200152A3 (en) 2003-01-28

Family

ID=7891421

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200152A HUP0200152A3 (en) 1998-12-17 1999-12-07 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites

Country Status (24)

Country Link
US (2) US6335363B1 (en)
EP (1) EP1140042B1 (en)
JP (1) JP2002532412A (en)
KR (1) KR20010089574A (en)
CN (1) CN1170528C (en)
AR (1) AR021690A1 (en)
AT (1) ATE390130T1 (en)
AU (1) AU1559500A (en)
BR (1) BR9916190A (en)
CA (1) CA2355300A1 (en)
CZ (1) CZ20012125A3 (en)
DE (2) DE19858253A1 (en)
HK (1) HK1041647B (en)
HR (1) HRPK20010442B1 (en)
HU (1) HUP0200152A3 (en)
IL (1) IL143717A0 (en)
NO (1) NO20012976L (en)
NZ (1) NZ512408A (en)
PL (1) PL349511A1 (en)
RU (1) RU2238090C2 (en)
SK (1) SK8562001A3 (en)
TR (1) TR200101750T2 (en)
WO (1) WO2000035429A1 (en)
ZA (1) ZA200103620B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1718677E (en) * 2003-12-19 2012-07-18 Genentech Inc Monovalent antibody fragments useful as therapeutics
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
NZ575118A (en) * 2006-09-01 2012-04-27 Du Pont Local topical administration formulations containing indoxacarb and a crystallization inhibitor
MX352732B (en) 2007-06-07 2017-12-06 Bayer Animal Health Gmbh Control of ectoparasites.
RU2364432C1 (en) * 2008-03-21 2009-08-20 Олег Николаевич Моисеев Therapy of helminthic invasions
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US9968564B2 (en) * 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US20100310726A1 (en) 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
AR086823A1 (en) 2011-06-30 2014-01-22 Genentech Inc ANTI-C-MET ANTIBODY FORMULATIONS, METHODS
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
EP2957557A1 (en) * 2014-06-17 2015-12-23 Novartis Tiergesundheit AG New compounds
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
JP7208137B2 (en) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド Compounds, compositions and methods
US11485733B2 (en) * 2017-06-30 2022-11-01 Bayer Animal Health Gmbh Azaquinoline derivatives
TW202334164A (en) 2022-01-12 2023-09-01 美商戴納立製藥公司 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175458C (en) * 1993-11-29 1999-03-02 Boyd L. Harrison Novel benzenesulfonylimine derivatives as inhibitors of il-1 action
US5559026A (en) * 1994-10-31 1996-09-24 American Cyanamid Company Genes encoding a novel family of potassium channels
DE19504379A1 (en) * 1995-02-10 1996-08-14 Hoechst Ag Substituted benzenesulfonylureas and thioureas, processes for their preparation and their use in the manufacture of pharmaceutical preparations and pharmaceutical preparations containing them
HRP970255B1 (en) * 1996-05-15 2003-10-31 Hoechst Ag Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents as well as medicaments containing them
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
DE19706675A1 (en) 1997-02-20 1998-08-27 Hoechst Ag Sulfonamide-substituted chromanes, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
DE19707656A1 (en) * 1997-02-26 1998-08-27 Hoechst Ag Sulphonamide-substituted fused 7-ring compounds, processes for their preparation, their use as medicaments or diagnostic agents and pharmaceutical preparations containing them
DE19742509A1 (en) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamide-substituted chromanes, processes for their preparation, their use as medicaments or diagnostic agents and pharmaceutical preparations containing them
DE19742508A1 (en) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamide-substituted chromanes, processes for their preparation, their use as medicaments or diagnostic agents and pharmaceutical preparations containing them
DE19748469A1 (en) * 1997-11-03 1999-05-06 Hoechst Marion Roussel De Gmbh Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
BR9916190A (en) 2001-09-11
ATE390130T1 (en) 2008-04-15
AU1559500A (en) 2000-07-03
SK8562001A3 (en) 2001-12-03
US6335363B1 (en) 2002-01-01
CZ20012125A3 (en) 2001-09-12
HRPK20010442B1 (en) 2003-10-31
CN1170528C (en) 2004-10-13
EP1140042A1 (en) 2001-10-10
ZA200103620B (en) 2002-06-04
WO2000035429A1 (en) 2000-06-22
IL143717A0 (en) 2002-04-21
JP2002532412A (en) 2002-10-02
NZ512408A (en) 2003-10-31
DE59914712D1 (en) 2008-05-08
PL349511A1 (en) 2002-07-29
US20020055537A1 (en) 2002-05-09
DE19858253A1 (en) 2000-06-21
AR021690A1 (en) 2002-07-31
RU2238090C2 (en) 2004-10-20
CN1330540A (en) 2002-01-09
HK1041647B (en) 2005-04-01
TR200101750T2 (en) 2002-01-21
NO20012976L (en) 2001-08-06
HUP0200152A3 (en) 2003-01-28
HK1041647A1 (en) 2002-07-19
HRP20010442A2 (en) 2002-06-30
KR20010089574A (en) 2001-10-06
CA2355300A1 (en) 2000-06-22
EP1140042B1 (en) 2008-03-26
NO20012976D0 (en) 2001-06-15

Similar Documents

Publication Publication Date Title
HUP0200152A2 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
BR0313371A (en) Compound, use of a compound and disease treatment method
CU23208A3 (en) OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
UY26130A1 (en) COMPOUNDS TO TREAT OBESITY
BRPI0411900A (en) antiviral compounds and methods
BRPI0415179A (en) amide derivatives such as ion channel ligands and pharmaceutical compositions and methods of employing them
BR0015992A (en) Compounds, their use, and therapeutic associations
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
EA200000759A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
DE60336664D1 (en) NONNUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
EE200200625A (en) Orthosubstituted anthranilic acid amides and their use as medicaments
EA200000911A1 (en) NEW CRYSTAL FORMS OF ANTI-VIRUS COMPOUND OF BENZIMIDAZOLE
UY27455A1 (en) DERIVATIVES N- (1,4,5,6-TETRAHIDRO-CICLOPENTAPIRAZOL -3-IL) - REPLACED. ITS OBTAINING AND USE AS DRUGS.
EA200500804A1 (en) Topical Anti-infective Compositions
ATE478662T1 (en) MEDICINAL SOLUTIONS CONTAINING MODAFINIL COMPOUNDS
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
SE9802208D0 (en) Novel compounds
EA200200742A1 (en) 1,2-DIARYLBENZYMIDAZOLEY FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF MICROGLY
DK1781277T3 (en) Combination composition comprising Ibuprofen and Paracetamol
EA200200137A1 (en) TREATMENT OF NEUROTIC DISORDERS
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
UY27451A1 (en) 2,5-DIAMIDOINDOLES REPLACED AND ITS USE
SE0004101D0 (en) New use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees